Poland· PL-100520943
Tepezza
A teprotumumab product containing teprotumumabum, registered in Poland by Amgen Europe B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Teprotumumab is registered in 10 of 19 countries.
Countries holding a registration under ATC L04AG13 (teprotumumab), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Teprotumumab · ATC L04AG13
10 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Teprotumumabum
- Manufacturer
- Amgen Europe B.V.
- Country
- Poland (PL)
- ATC code
- L04AG13
- ATC class
- Teprotumumab
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin08715131030797
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
55 interactions on record for teprotumumab.
Graded by severity as the source publishes them — 55 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Teprotumumab · interactions on record
55 records
- 55 moderate
Most severe, free to view
- LiraglutidA08AX02moderate
- SemaglutidA08AX03moderate
- Insulin (human)A10AB01moderate
- Insulin lisproA10AB04moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Teprotumumab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTepezza 500 mgAmgen Europe
- SwitzerlandTepezza 500 mg, Pulver für ein Konzentrat zur Herstellung einer InfusionslösungAmgen Switzerland AG
- CzechiaTEPEZZAAmgen Europe B.V., Breda
- SpainTEPEZZA 500 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONAmgen Europe B.V.
- FinlandTEPEZZAAmgen Europe B.V.
- United KingdomTepezza 500mg powder for concentrate for solution for infusion vialsAmgen Ltd
- IrelandTEPEZZA 500 mg powder for concentrate for solution for infusionAmgen Europe B.V.,
- IcelandTepezzaAmgen Europe B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tepezza
- Norway · Tepezza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fc51f539-05ac-4ea9-9c94-ac278d0b0a2b GET /v1/drugs/fc51f539-05ac-4ea9-9c94-ac278d0b0a2b?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek do sporządzania koncentratu roztworu do infuzji",
"source": "urpl",
"strength": "500 mg",
"packaging": "08715131030797 ¦ Rpz ¦ EU/1/25/1941/001 ¦ 162765\n1 fiol. 500 mg proszku",
"substance": "Teprotumumabum 500 mg",
"common_name": "Teprotumumabum",
"pl_product_id": "100520943",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about teprotumumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.